EP Patent

EP2802314B1 — A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.

Assigned to XSpray Microparticles AB · Expires 2020-11-25 · 5y expired

What this patent protects

Patent listed against osimertinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2802314B1
Jurisdiction
EP
Classification
—
Expires
2020-11-25
Drug substance claim
No
Drug product claim
No
Assignee
XSpray Microparticles AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.